• What is it An autoimmune syndrome characterized by anti–tRNA synthetase antibodies (e.g., anti–Jo-1), with clinical triad: inflammatory myopathy, arthritis, interstitial lung disease (ILD).
    Caused by Autoantibody-mediated immune injury targeting aminoacyl–tRNA synthetases; immune complex deposition and inflammation in muscle, lung, and joints.
    Resulting in Chronic inflammatory and fibrotic injury to the lung interstitium and airways, leading to ILD, small-airway disease, and traction bronchiectasis.
    Structural changes Interstitial thickening, ground-glass opacities (early activity), perilobular consolidation (OP component), fibrosis with reticulation, traction bronchiectasis, and mosaic attenuation (air-trapping).
    Functional changes Restrictive ventilatory defect (ILD), reduced DLCO, hypoxemia on exertion, impaired clearance due to bronchiectasis; small-airway obstruction in late/upper lobe disease.
    Diagnosis Clinical (myositis, arthritis, mechanic’s hands, Raynaud’s), serology (anti–Jo-1 or other anti-synthetase antibodies), imaging (HRCT patterns: NSIP, OP, NSIP/OP overlap, fibrotic progression), sometimes biopsy.
    Complications Progressive pulmonary fibrosis, chronic hypoxemia, pulmonary hypertension, respiratory failure.
    Treatment Immunosuppression (corticosteroids, mycophenolate, azathioprine, cyclophosphamide, rituximab), antifibrotics in select cases, pulmonary rehab, O₂, management of PH.

  • Structural Changes by Scale

    Level Pathobiology Radiologic Correlate
    Organelle – Endoplasmic reticulum stress and misfolded proteins from immune attack on aminoacyl-tRNA synthetase.
    – Mitochondrial dysfunction from chronic inflammation → ↑ ROS, apoptosis.
    – Impaired protein synthesis (antibody targets are translation enzymes).    		 → Triggers cell injury and death in alveolar epithelium and bronchiolar epithelium.
    Cellular – Type II pneumocytes: injury, apoptosis, aberrant repair → loss of alveolar-capillary interface (ground-glass → fibrosis).
    – Fibroblasts/myofibroblasts: proliferation, ECM deposition → reticulation, traction bronchiectasis.
    – Bronchiolar epithelium: lymphocytic infiltration, mural fibrosis, smooth muscle hypertrophy → airway wall thickening.
    – Endothelial cells: immune-mediated vasculopathy, capillary loss → contributes to peribronchovascular involvement.    		 → Early GGO/consolidation (cell injury/inflammation).
    → Fibrotic NSIP with traction bronchiectasis.
    → Airway wall thickening, mosaic attenuation from small-airway obstruction.
    Tissue (Microscopic) – Interstitial compartment: lymphoplasmacytic infiltrates, peribronchovascular distribution, later collagen deposition.
    – Airways: cellular bronchiolitis (lymphoid aggregates around small airways) → constrictive bronchiolitis (fibrotic narrowing).
    – Alveolar units: loss of architecture, traction on airways → dilated bronchovascular bundles.    		 → Peribronchovascular thickening, lower lobe fibrosis, traction bronchiectasis.
    → Upper lobe airway wall thickening without consolidation = bronchiolitis phenotype.
    Tissue (Macroscopic) – Lower lobes: fibrotic NSIP/OP overlap → coarse reticulation, bronchiectasis, volume loss.
    – Upper lobes: predominantly bronchiolitis and airway wall thickening; minimal ground-glass → looks like chronic bronchitis/airway-predominant ILD.    		 → CT: lower = fibrotic NSIP; upper = airway disease (bronchiolitis).
    CT Level Integration of above:
    • Lower lobes → bronchovascular fibrosis, traction bronchiectasis, reticulation.
    • Upper lobes → airway wall thickening, “tree-in-bud”/centrilobular nodularity if active, or mosaic attenuation if fibrotic/constrictive.    		 The pattern you describe matches fibrotic NSIP below + airway-predominant disease above, both under the umbrella of antisynthetase ILD.

  • Table 3. Comparative Radiology — Antisynthetase vs Other ILDs

    Disease Key Radiologic Distinction
    ASyS ILD Lower lung, peribronchovascular NSIP/OP overlap, traction bronchiectasis, air-trapping.
    IPF (UIP) Basal/subpleural honeycombing, temporal heterogeneity, no subpleural sparing.
    Chronic HP Mid/upper lobe, lobular air-trapping, centrilobular nodules, mosaic attenuation.
    CTD-ILD (RA, SSc) RA: upper/mid fibrosis, airway disease; SSc: basilar fibrosis + esophageal dilation.

    Key Points & Pearls

    • NSIP and OP overlap is most typical pattern in ASyS.

    • Traction bronchiectasis in lower lobes signals fibrotic progression.

    • Upper lobe small-airway disease may emerge with time — uncommon in other CTD-ILDs.

    • Active ground-glass/consolidation indicates treatable inflammation; absence suggests “burnt out” fibrotic stage.

    • Always correlate with antibody subtype — anti–PL-7, PL-12 often have more severe ILD.

  • ASyS ILD as a two-compartment process:

    1. Interstitial-predominant (lower lobes) → NSIP/OP evolving to fibrosis.

    2. Airway-predominant (upper lobes) → chronic bronchiolitis and bronchiectasis.

  • The imaging duality reflects the biology: immune attack not only on alveolar epithelium but also bronchiolar epithelium and peribronchovascular connective tissue.

Related Links

Google ImagesGoogleYouTubeWikipediaRadiopediaRadiographicsPubMedChatGPTOpenEvidence